CClinicalTrials.gg
Sign In
CompletedNCT01709955Updated Oct 18, 2012

The Effects of Glucomannan on Weight Loss

A Phase 1 interventional study of Glucomannan and Placebo in Obesity, sponsored by Northeast College of Health Sciences. Completed. Open to participants aged 21 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2012-10-18.

Sponsored by Northeast College of Health Sciences · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
21 Years to 60 Years
Sex
All
01

Study summary

The purpose of this study is to determine if the herb, Glucomannan, is an effective non-pharmacological appetite suppressant for overweight or Class I obese patients. The study design will not include any other lifestyle changes which enhance weight loss in order to completely isolate the effects of Glucomannan as a non-pharmacological appetite suppressant.

02

Conditions studied

  • Obesity

Browse trials for

Keywords

  • Obesity
  • Overweight
  • Glucomannan
03

In context

Obesity

6,296 studies on the registry are indexed under Obesity; 1,692 are open to participants now.

This study's enrollment of 43 is below the median of 78 across 4,878 interventional studies indexed under Obesity.

Browse Obesity studies →

Lead sponsor

Northeast College of Health Sciences is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:Subjects will be recruited based upon the category of them wanting to lose 50 pounds.

Subjects must be able to swallow the capsule whole with water.

Exclusion Criteria:

  1. Self-reported use of prescription medication other than hormonal birth control (such as medication for diabetes, hypertension hypothyroidism, heart disease, cancer, etc.)
  2. Pregnancy
  3. Age younger than 21 or older than 60 years of age.
  4. Screening for hypertension during the first laboratory visit that reveals a systole greater than 120 and a diastole greater than 90.
  5. BMI calculations based upon height and weight measurements at the first laboratory visit that reveal a BMI less than 25 or greater than 35.
  6. Self-reported iron-deficiency anemia, osteoporosis, and hypoglycemia.
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Gucomannan

    Dietary Supplement: Glucomannan

  • Placebo comparator
    Placebo pill

    Other: Placebo

Interventions

  • Dietary supplementGlucomannan

    750 MG of Glucomannan in capsule form

  • OtherPlacebo

    750 mg of Cellulose powder in a capsule form

06

What researchers measure

Primary outcomes

  1. Weight Loss

    Time frame: 30 Days

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 18, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01709955
Lead sponsor
Northeast College of Health Sciences
Responsible party
Denise Holtzman MS DC (Associate professor, Northeast College of Health Sciences) — Principal investigator
First posted
Oct 18, 2012
Start date
Feb 2011
Primary completion
Jul 2011
Completion
Jul 2011
Last update
Oct 18, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Obesity→

Other studies from this sponsor

Northeast College of Health Sciences

Start the discussion